-
公开(公告)号:US20220233532A1
公开(公告)日:2022-07-28
申请号:US17580768
申请日:2022-01-21
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/506 , A61K9/20 , A61K9/00 , A61K9/28 , A61K45/06
摘要: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
-
公开(公告)号:US20220168285A1
公开(公告)日:2022-06-02
申请号:US17671207
申请日:2022-02-14
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/44 , A61K31/4439 , A61K9/14 , A61K9/16 , A61K31/5377 , A61K47/38 , A61K9/00 , A61K9/51 , A61K31/444 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K47/32 , A61K31/517
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20220296575A1
公开(公告)日:2022-09-22
申请号:US17829736
申请日:2022-06-01
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/44 , A61K31/517 , A61K9/51 , A61K31/437 , A61K31/506 , A61K9/14 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K47/32 , A61K47/38 , A61K31/444 , A61K9/16 , A61K9/00
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20220160687A1
公开(公告)日:2022-05-26
申请号:US17671157
申请日:2022-02-14
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/44 , A61K31/4439 , A61K9/14 , A61K9/16 , A61K31/5377 , A61K47/38 , A61K9/00 , A61K9/51 , A61K31/444 , A61K31/437 , A61K31/4545 , A61K31/506 , A61K47/32 , A61K31/517
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
公开(公告)号:US20230121325A1
公开(公告)日:2023-04-20
申请号:US18064383
申请日:2022-12-12
申请人: XSPRAY PHARMA AB
IPC分类号: A61K9/20 , A61K31/506
摘要: The present disclosure relates to the field of pharmaceutical compositions. Furthermore, the present invention relates to an immediate release pharmaceutical composition in the form of a non-effervescent tablet composition comprising dasatinib and a gas generating agent.
-
公开(公告)号:US20220117947A1
公开(公告)日:2022-04-21
申请号:US17552768
申请日:2021-12-16
申请人: XSPRAY PHARMA AB
IPC分类号: A61K31/44 , A61K31/517 , A61K9/51 , A61K31/437 , A61K31/506 , A61K9/14 , A61K31/4439 , A61K31/4545 , A61K31/5377 , A61K47/32 , A61K47/38 , A61K31/444 , A61K9/16 , A61K9/00
摘要: The present invention relates to the field of methods for providing pharmaceutical compositions comprising poorly water-soluble drugs. In particular the present invention relates to compositions comprising stable, amorphous hybrid nanoparticles, comprising at least one protein kinase inhibitor and at least one polymeric stabilizing and matrix-forming component, useful in pharmaceutical compositions and in therapy.
-
-
-
-
-